Nanogen Begins Shipments of NanoChip 400 Systems

Oct 19, 2005, 01:00 ET from Nanogen, Inc.

    SAN DIEGO, Oct. 19 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq:   NGEN),
 developer of advanced diagnostic products, announced today that it has begun
 shipping its second-generation instrument, the NanoChip(R) 400, both
 domestically and to Europe.  The general laboratory system for molecular
 biology applications utilizes the company's improved NanoChip(R) 400-site
 electronic microarray, upon which homebrew molecular assays can be developed
 in clinical and research laboratories.  Building on features customers valued
 with the first-generation NanoChip(R) Molecular Biology Workstation and
 100-site chip, the new multi-purpose system combines sample and reagent
 handling robotics with detection in an instrument half the size of its
 predecessor.  The open and robust platform creates the opportunity for
 laboratories to use one system for multiple molecular applications, including
 the detection of single nucleotide polymorphisms (SNPs) and multi-gene targets
 like those tested for pharmacogenetics.
     The NanoChip(R) 400 cartridge used with the system is a blank microarray
 template that constructs the user defined panel of genetic markers on one chip
 at the time of sample testing.  The cartridge has 400 test sites that can be
 used for any combination of multiple genes and multiple samples and can be
 used multiple times until the 400 test sites are used.  This cartridge
 reusability makes the NanoChip(R) 400 system easier and more cost-effective to
 use than research-grade thousand-gene chip arrays and more suitable than
 polymerase chain reaction (PCR) when multi-allele or multi-gene assays are of
 interest. The system is ideal for mid- to high-volume laboratories where the
 need to streamline testing and workflow is a high priority.
     "I am very excited about the new instrument," said Steve Cook, manager of
 molecular diagnostics at Lahey Clinic in Boston. "I think it is going to be
 great for us as a customer and great for Nanogen as a vendor.   The walk-away
 capability will be a valuable improvement over the Molecular Biology
 Workstation and will allow us to consolidate and streamline our workflow.
 This capability may open up the instrument for us to do more homebrew
     "Our first deliveries of the NanoChip(R) 400 system mark a significant
 milestone in the development of our company," said Howard C. Birndorf, Nanogen
 chairman and CEO. "Moving products out of development and into our commercial
 product portfolio will contribute significantly to our revenue in the coming
 quarters. We're delighted to be able to offer new tools that facilitate the
 understanding of disease and can ultimately be used to improve the health of
     The NanoChip 400(R) is manufactured by Nanogen's long-standing
 collaborator Hitachi Instruments Group under the Food and Drug
 Administration's Quality System Regulation.  Nanogen has self-certified the
 instrument for European CE Mark.  Additional information is available by
 calling 877-NANOGEN or by visiting
     About Nanogen, Inc.
     Nanogen's advanced technologies provide researchers, clinicians and
 physicians worldwide with improved methods and tools to predict, diagnose, and
 ultimately help treat disease.  The company's products include real-time PCR
 reagents, the NanoChip(R) electronic microarray platform and a line of rapid
 diagnostic tests. Nanogen's ten years of pioneering research involving
 nanotechnology holds the promise of miniaturization and continues to be
 supported for its potential for diagnostic and biowarfare applications. For
 additional information please visit Nanogen's website at
     Forward-Looking Statement
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including whether
 products under development can be successfully developed and commercialized,
 whether patents owned or licensed by Nanogen will be developed into products,
 whether the patents owned by Nanogen offer any protection against competitors
 with competing technologies, whether results reported by our customers or
 partners can be identically replicated, and other risks and uncertainties
 discussed under the caption "Factors That May Affect Results" and elsewhere in
 Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
 Exchange Commission.  These forward-looking statements speak only as of the
 date hereof.  Nanogen disclaims any intent or obligation to update these
 forward-looking statements.

SOURCE Nanogen, Inc.